Tumor markers

Global Prostate Cancer Diagnostics Market Report 2021-2027: Preliminary Screening, Confirmatory Test, PCA3, Trans-rectal Ultrasound, Biopsy - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Oncology, Anatomy, Branches of biology, Prostate cancer, Clinical medicine, Histopathology, Tumor markers, PCA3, Prostate, Cancer, Prostate biopsy, Prostate cancer screening

The "Prostate Cancer Diagnostics Market Global Forecast By Type (Preliminary Screening, Confirmatory Test, PCA3, Trans-rectal Ultrasound, Biopsy), End Users, Regions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prostate Cancer Diagnostics Market Global Forecast By Type (Preliminary Screening, Confirmatory Test, PCA3, Trans-rectal Ultrasound, Biopsy), End Users, Regions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Prostate Cancer Diagnostics Market will be US$ 7.5 Billion by 2027, from US$ 1.6 Billion in 2020
    Global Prostate Cancer Diagnostics Industry is expected to grow with a double-digit staggering CAGR of 24.69% during 2020-2027.
  • Cancer, especially prostate cancer, has impacted more to men than women as their percentage was much lesser than men.
  • Our study investigated that, Prostate cancer is the 2nd most common cancer in men across developed countries to date.

Global Team of Cancer Genetic Specialists Provides New Guidance for Individuals with PALB2 Gene Variants: ACMG Clinical Practice Resource to Help Guide Clinical Management of Patients at Increased Risk of Breast, Pancreatic and Ovarian Cancers

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Breast cancer, Cancer, Tumor markers, Tumor suppressor genes, Genetics, Hereditary cancers, BRCA2, BRCA1, PALB2, Variant of uncertain significance, BRCA mutation

Germline pathogenic/likely pathogenic (P/LP) variants in PALB2 were first associated with increased cancer risk in 2007 and clinical testing has been available since then.

Key Points: 
  • Germline pathogenic/likely pathogenic (P/LP) variants in PALB2 were first associated with increased cancer risk in 2007 and clinical testing has been available since then.
  • It has come to be considered as the third most important breast cancer gene after BRCA1 and BRCA2.
  • While the range of the cancer risk estimates overlap with BRCA1/2, it is lower in PALB2, so individualized estimates are important for management decisions.
  • "First, it reflects a commitment of the ACMG to develop guidance for use of germline genetic information for the treatment of patients with cancer.

Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer

Retrieved on: 
Thursday, April 15, 2021
Branches of biology, Clinical medicine, Tumor suppressor genes, Medical genetics, Breast cancer, Tumor markers, BRCA2, Penetrance, P53, Genetic testing, Colorectal cancer, Cancer

In the study, 361 colorectal cancer patients received germline genetic testing using a panel that included more than 80 genes linked to increased cancer risk.

Key Points: 
  • In the study, 361 colorectal cancer patients received germline genetic testing using a panel that included more than 80 genes linked to increased cancer risk.
  • Cancer-linked genetic changes were found in 15.5% (n=56) of patients predominantly in moderate and high penetrance cancer susceptibility genes such as APC, BRCA2 and TP53.
  • Invitae\'s goal is to aggregate the world\'s genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
  • These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.\n'

Helio Health Announces China NMPA Acceptance of Registration Application for Helio Liver Test

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Hepatology, Clinical medicine, Medicine, Tumor markers, Cancer, Hepatocellular carcinoma, Liver cancer, Alpha-fetoprotein, Circulating free DNA, AFP-L3, Liver tumor

IRVINE, Calif., March 24, 2021 /PRNewswire/ -- Helio Health , an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the China National Medical Products Administration (NMPA) has accepted the Company's registration application for its Helio Liver Test, a cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC) or liver cancer.

Key Points: 
  • IRVINE, Calif., March 24, 2021 /PRNewswire/ -- Helio Health , an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the China National Medical Products Administration (NMPA) has accepted the Company's registration application for its Helio Liver Test, a cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC) or liver cancer.
  • The study evaluated 1,093 individuals in China with HCC and benign liver diseases as well as healthy controls.
  • "We look forward to working with the Chinese regulatory authorities to advance registration of the Helio Liver Test in China and we plan to share the encouraging details of the VICTORY trial at a later date."
  • The Helio Liver Test was validated in an independent cohort of 631 subjects, including patients with HCC (n=291) and age-matched healthy controls (n=340), compared to serum alpha-fetoprotein (AFP) alone, a well-known marker for liver cancer.

Berry Oncology Announces Novel Diagnostic Method for Liver Cancer Achieved Greater Accuracy and Sensitivity Compared to Existing Non-Invasive Methods

Retrieved on: 
Wednesday, February 24, 2021
Medical specialties, Hepatology, Clinical medicine, Medicine, Tumor markers, Oncology, Des-gamma carboxyprothrombin, Liver cancer, Cancer, Hepatocellular carcinoma

Researchers then used a logistic regression method to construct a weighted diagnostic model based on the performance of these four features.

Key Points: 
  • Researchers then used a logistic regression method to construct a weighted diagnostic model based on the performance of these four features.
  • The novel diagnostic model, called HIFI, achieved a sensitivity of 95.42%, a specificity of 97.83%, and an AUC of 0.996 in the study, a higher accuracy in differentiating HCC from liver cirrhosis than existing diagnosis tests measuring AFP or PIVKA-II.
  • According to Berry Oncology CEO Jun Zhou, the result of this study is a milestone for Berry Oncology in tumor screening and early detection.
  • For cancer early detection, we have launched a series of clinical research projects for early screening and early diagnosis, covering liver cancer, lung cancer, gynecologic cancer, and etc.

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Retrieved on: 
Tuesday, January 19, 2021
Branches of biology, Breast cancer, Clinical medicine, Tumor markers, Tumor suppressor genes, Medical genetics, Medical tests, BRCA2, BRCA1, Genetic testing, Prostate cancer, Cancer

Myriad estimates there are more than 78,000 cases of prostate cancer and 40,000 cases of pancreatic cancer per year in Japan.

Key Points: 
  • Myriad estimates there are more than 78,000 cases of prostate cancer and 40,000 cases of pancreatic cancer per year in Japan.
  • With the reimbursement decision, approximately 20,000 patients in Japan will now qualify to receive genetic testing.
  • Group Holdings, Inc. to expand the commercialization of the BRACAnalysis Diagnostic System in Japan.
  • BRACAnalysis is a diagnostic system that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.

Publication of a Health Economic Analysis Demonstrates IsoPSA® Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs

Retrieved on: 
Wednesday, January 13, 2021
Research, Medical devices, Clinical trials, Biotechnology, Health, General Health, Other Science, Science, Oncology, Medical specialties, Branches of biology, Clinical medicine, Prostate cancer, Histopathology, Tumor markers, Prostate-specific antigen, Breast cancer, Cancer, Medical test, Prostate, Cancer prevention

The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics IsoPSA test for the detection of clinically significant prostate cancer.

Key Points: 
  • The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics IsoPSA test for the detection of clinically significant prostate cancer.
  • Model inputs included established determinants of IsoPSA diagnostic accuracy (i.e., AUC, sensitivity, specificity, and predictive value), IsoPSA cost, and conservative estimates of costs associated with conventional prostate cancer diagnostic evaluations and treatment.
  • Given this new information, we believe that IsoPSA holds considerable potential to shift the paradigm for prostate cancer detection and management.
  • Its portfolio of non-invasive cancer diagnostics will be expanding from prostate cancer to breast cancer and lung cancer, infectious diseases, and certain neurological diseases, such as Alzheimers disease.

 Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma

Retrieved on: 
Monday, October 5, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Hepatology, Tumor markers, Medicine, Hepatocellular carcinoma, Alpha-fetoprotein

ET140202 and ET140203 utilize Eurekas proprietary ARTEMIS cell receptor platform engineered with a TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.

Key Points: 
  • ET140202 and ET140203 utilize Eurekas proprietary ARTEMIS cell receptor platform engineered with a TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.
  • We are very excited to initiate our ET140203 ARYA-1 clinical trial, said Dr. Cheng Liu, President and CEO of Eureka Therapeutics.
  • Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers.
  • ET140203, the Companys lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients

Retrieved on: 
Friday, August 28, 2020
Medical specialties, Hepatology, Clinical medicine, Cancer, Hepatocellular carcinoma, Brachyury, Tumor markers, Brivanib alaninate

One patient out of four dosed with 5 billion or more cells had a complete response, which was reported previously.

Key Points: 
  • One patient out of four dosed with 5 billion or more cells had a complete response, which was reported previously.
  • The data also demonstrate an acceptable safety profile in patients with hepatocellular carcinoma (HCC).
  • We remain encouraged by the potential of this therapy and we are fully committed to developing ADPA2AFP for people with HCC.
  • Dr. Bruno Sangro of Clinica Universidad de Navarra presented data from Cohort 3 and the expansion phase of the ADP-A2AFP Phase 1 trial during an oral presentation at ILC.

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

Retrieved on: 
Tuesday, July 7, 2020
Breast cancer, Cancer, Health, RTT, Hereditary cancers, Epidemiology, Tumor markers, Tumor suppressor genes, Cancer syndrome, BRCA1, Hereditary breast–ovarian cancer syndrome, Risk factors for breast cancer

The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations.

Key Points: 
  • The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations.
  • Historically weve considered breast cancer risk most significant for women diagnosed with pathogenic mutations in hereditary cancer genes.
  • It showed that independent of other hereditary breast cancer gene mutations (e.g., BRCA1), Myriads polygenic risk score can add great value and precision to breast cancer risk estimates.
  • This translated to women in the top PRS percentile having a three-fold higher risk of breast cancer than an average risk patient.